arrow
J

Julius Strauss

national institutes of health (nih) - usa
H指数:21
被引数:2,532

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The quadruple immunotherapy for colorectal cancer (QuICC) trial for mismatch repair-proficient metastatic colorectal cancer

针对错配修复 proficient 的转移性结直肠癌的四联免疫疗法(QuICC)试验

2026-03-012
PRE
PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancer

PRGN-2009和bintrafusp alfa用于晚期或转移性人乳头瘤病毒相关癌症患者

2025-03-210
OA
A deep-learning framework to predict cancer treatment response from histopathology images through imputed transcriptomics

一种深度学习框架,通过转录组学预测组织病理学图像的癌症治疗反应

2024-07-035
OA
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma

M9241 (NHS-IL12) 联合阿维鲁单抗在晚期实体瘤患者中的首次人类Ib期试验,包括晚期尿路上皮癌患者的剂量扩展

2023-05-269
OAAI
Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer
2021-09-0326
OAAI
Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)
2021-03-2438
OAAI
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
2020-12-15106
OAAI
Evaluating biomarkers in metastatic castration resistant prostate cancer (mCRPC) patients (Pts) treated with enzalutamide (Enza): PSA, circulating tumor cell (CTC) counts, AR-V7 status, PET imaging vs. CT & Tc99 scans
2020-09-010
OAAI